Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | MPI | P34949 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2338047 | 1.00 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL7153437 | 1.00 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL448041 | 1.00 | AKR1B1 (0.36) | AKR1B1MPITHRB | |
| SCHEMBL3281934 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL16431695 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL14659599 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL3276506 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL20281001 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL17866955 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB | |
| SCHEMBL6473099 | 0.93 | AKR1B1 (0.35) | AKR1B1MPITHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1101228-C | Treatment of conditions and disease | HYALURONIC ACID PHARMACEUTICAL (CA) | 2003-02-12 | — | — | CN | claimed |
| CN-1051503-A | Disease and treatment of diseases | NORPHARMCO INC (CA) | 1991-05-22 | — | — | CN | claimed |
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2025-04-24 | — | — | US | disclosed |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | ENGENE, INC. (CA) | 2024-09-03 | — | — | US | disclosed |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | HERCULES CAPITAL, INC. | 2022-05-05 | — | — | US | disclosed |
| EP-3970697-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | Engene, Inc. (CA) | 2022-03-23 | — | — | EP | disclosed |
| WO-2022026463-A1 | OXYTOCIN ANALOGUES AND METHODS FOR USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2022-02-03 | — | — | WO | disclosed |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | HERCULES CAPITAL, INC. | 2021-11-09 | — | — | US | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| EP-3049473-B1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | ENGENE INC (CA) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020210175-A1 | NITROREDUCTASE-RELEASABLE PRO-DRUGS AND METHODS FOR USING THE SAME | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-10-15 | — | — | WO | disclosed |
| EP-1919486-A2 | CORE 2 GLCNAC-T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2008-05-14 | — | — | EP | disclosed |
| EP-1909802-A2 | STEROIDAL GLYCOSIDE COMPOUNDS AS CORE 2 GLCNAC-T INHIBITORS | BTG International Limited (GB) | 2008-04-16 | — | — | EP | disclosed |
| US-7330748-B2 | Method for determining in vivo concentration of a metabolite | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070010461-A1 | Core 2 GlcNAc-T inhibitors | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
| WO-2007003948-A2 | CORE 2 GLCNAC-T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| WO-2007003957-A2 | STEROIDAL GLYCOSIDE COMPOUNDS AS CORE 2 GLCNAC- T INHIBITORS | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | WO | disclosed |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | BTG INTERNATIONAL LIMITED (GB) | 2007-01-11 | — | — | US | disclosed |
| CN-1101228-C | Treatment of conditions and disease | HYALURONIC ACID PHARMACEUTICAL (CA) | 2003-02-12 | — | — | CN | disclosed |
| CN-1051503-A | Disease and treatment of diseases | NORPHARMCO INC (CA) | 1991-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127925-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885MPI 2113/4885THRB 3433/4885 |
| US-11167045-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885MPI 2113/4885THRB 3433/4885 |
| US-20070010461-A1 | Core 2 GlcNAc-T inhibitors | MAN2A1, CSGALNACT1, MAN2B1 | AKR1B1 704/4885MPI 105/4885THRB 557/4885 |
| US-12076418-B2 | Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885MPI 2113/4885THRB 3433/4885 |
| US-20070010462-A1 | Core 2 GlcNAc-T inhibitors III | CSGALNACT1, ENGASE, GALNT6 | AKR1B1 421/4885MPI 384/4885THRB 610/4885 |
| US-20220133907-A1 | DUALLY DERIVATIZED CHITOSAN NANOPARTICLES AND METHODS OF MAKING AND USING THE SAME FOR GENE TRANSFER IN VIVO | CSGALNACT1, CHI3L2, LNPEP | AKR1B1 3046/4885MPI 2113/4885THRB 3433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.